EPPA
13.1.2023 05:01:38 CET | Business Wire | Press release
The European Paper Packaging Alliance (EPPA) has this week welcomed a new President and Director General.
At EPPA’s General Assembly on 9 January, Antonio D’Amato, CEO of Seda International Packaging Group and former president of Confindustria, the Confederation of Italian Industry, has been elected President. He took over from Eric Le Lay, President of Huhtamaki Fibre Food Service who is now Vice-President of the Alliance.
EPPA also appointed Matti Rantanen, an experienced packaging expert and public affairs professional, as its new Director General.
2023 will be a pivotal year for the European packaging industry as discussions on the EU’s proposed Packaging and Packaging Waste Regulation heat up. The European Commission is proposing the mass implementation of reusable packaging across a range of sectors - in spite of life cycle analysis clearly showing it to be the least sustainable choice. EPPA will be making the case for the best environmental, renewable and recyclable single-use paper packaging.
Incoming EPPA President Antonio D'Amato said:
"I am honoured to take on the Presidency of EPPA again and thank all its members, particularly Eric Le Lay, for their excellent work over the past year. EPPA increasingly represents the leading companies in Europe’s paper packaging supply chain, from forest, paper and board producers to converters and brand owners as well. We will maintain our focus on continuing the innovative, sustainable development of single-use paper packaging that is fully integrated in the circular economy.
Our mission is increasingly focused on supporting policymakers to make decisions based on solid scientific evidence. Single-use paper packaging has an essential role to play in reducing CO2 emissions while simultaneously reducing food waste, avoiding water stress and protecting consumer health."
Eric Le Lay, President of Fiber & Foodservice at Huhtamaki and Vice-President of EPPA said:
“I am delighted to pass on the torch to Antonio D’Amato this year. He brings a wealth of experience to the role. Our biggest challenge is to engage constructively on the complex Packaging and Packaging Waste Regulation file. We will continue to make the case for recyclable, renewable paper-based packaging at the heart of Europe’s circular economy and ensure that policies are based on science and evidence.”
Matti Rantanen, Director General of the European Paper Packaging Alliance added:
“I am excited to join EPPA and work to promote recyclable and renewable paper packaging as a solution to achieve a fully circular economy. Reviewing the EU’s packaging and packaging waste rules is crucial, yet it must be done rationally and in accordance with scientific evidence. EPPA’s studies have shown that in quick-service restaurants, both for in-store consumption and takeaway services, single-use paper packaging is simply better for the environment, the economy and consumer health. I am dedicated to getting this message across. As we continue to feel the effects of climate change and of the global economic crisis everyday, EPPA will continue to offer facts and evidence that should be acknowledged by policy makers.”
ENDS
About EPPA:
The European Paper Packaging Alliance is a non-for-profit food and foodservice packaging association. The priorities of the Alliance are to find concrete solutions to increase recycling and to reduce carbon emissions of food and foodservice packaging without compromising food safety and human health protection. More information is available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005686/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
